Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSERT-EXT long-term open-label odevixibat study in Alagille syndrome
2023-509028-17-00Phase 3Authorised
- Sponsor
- Ipsen
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in Alagille syndrome (ALGS), sponsored by Ipsen. Planned start Jan 2022; status: authorised.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on 2023-509028-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509028-17-00.